Unity Biotechnology Inc (UNBX)

Currency in USD
0.056
0.000(0.00%)
Closed·
Showing Unity Biotech historical data. For real-time data please try another search
Fair Value
Day's Range
0.0560.062
52 wk Range
0.0493.100
Key Statistics
Prev. Close
0.056
Open
0.056
Day's Range
0.056-0.062
52 wk Range
0.049-3.1
Volume
71.71K
Average Volume (3m)
240.72K
1-Year Change
-95.82%
Book Value / Share
-0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
UNBX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Unity Biotechnology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Unity Biotechnology Inc Company Profile

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Compare UNBX to Peers and Sector

Metrics to compare
UNBX
Peers
Sector
Relationship
P/E Ratio
0.0x−3.3x−0.7x
PEG Ratio
0.000.240.00
Price/Book
−4.7x2.8x2.6x
Price / LTM Sales
-9.5x3.4x
Upside (Analyst Target)
-37.9%37.8%
Fair Value Upside
Unlock18.1%5.3%Unlock

Earnings

Latest Release
Apr 22, 2025
EPS / Forecast
-0.43 / -0.37
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

UNBX Income Statement

People Also Watch

894.40
ASML
+0.75%
42.710
ARQQ
+9.43%
73.700
ASTS
+2.76%
7.010
LAES
+22.55%
132.55
CRWV
+7.47%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.